A carregar...
The molecular targets of approved treatments for pulmonary arterial hypertension
Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an addition...
Na minha lista:
| Publicado no: | Thorax |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4717417/ https://ncbi.nlm.nih.gov/pubmed/26219978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2015-207170 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|